InvestSMART

Neuren Pharmaceuticals Limited (ASX: NEU) - Announcements

- Current share price for NEU : $23.240

ASX company news and announcements for Neuren Pharmaceuticals Limited (NEU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neuren Pharmaceuticals Limited (NEU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neuren Pharmaceuticals Limited (NEU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neuren Pharmaceuticals Limited (NEU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,946 Appendix 4C - quarterly 17 Oct 2014 4:15PM $0.086 $23.240 risen by 26,923.26%
$2,946 Enrolment commences in Neuren's Concussion Phase 2 trial 8 Sep 2014 10:01AM $0.100 $23.240 risen by 23,140%
$2,946 Half Yearly Report and Accounts 28 Aug 2014 7:31AM $0.100 $23.240 risen by 23,140%
$2,946 Neuren advances NNZ-2591 towards IND application 12 Aug 2014 9:20AM $0.095 $23.240 risen by 24,363.16%
$2,946 Appendix 4C - quarterly 18 Jul 2014 1:25PM $0.089 $23.240 risen by 26,012.36%
$2,946 US$3m increase to US Army grant and INTREPID outlook update 17 Jul 2014 1:19PM $0.089 $23.240 risen by 26,012.36%
$2,946 Neuren receives ethics approval to start Concussion trial 10 Jul 2014 11:47AM $0.088 $23.240 risen by 26,309.09%
$2,946 Neuren completes enrolment in Phase 2 trial in Rett Syndrome 26 Jun 2014 8:50AM $0.082 $23.240 risen by 28,241.46%
$2,946 Neuren receives new US patent for NNZ-2591 4 Jun 2014 11:01AM $0.067 $23.240 risen by 34,586.57%
$2,946 Appendix 4C - quarterly 30 Apr 2014 7:09PM $0.087 $23.240 risen by 26,612.64%
$2,946 Preliminary Final Report and audited Financial Statements 27 Feb 2014 8:27AM $0.095 $23.240 risen by 24,363.16%
$2,946 Appendix 4C - quarterly 31 Jan 2014 4:59PM $0.100 $23.240 risen by 23,140%
$2,946 Neuren reports progress in NNZ-2566 clinical trial programs 28 Jan 2014 10:47AM $0.100 $23.240 risen by 23,140%
$2,946 Share Purchase Plan offer documents 30 Oct 2013 5:21PM $0.120 $23.240 risen by 19,266.67%
$2,946 Appendix 4C - quarterly 30 Oct 2013 5:13PM $0.120 $23.240 risen by 19,266.67%
$2,946 Orphan drug designation from FDA for NNZ-2566 in Fragile X 30 Oct 2013 10:21AM $0.120 $23.240 risen by 19,266.67%
$2,946 Placement of $21.5m to accelerate execution of strategy 22 Oct 2013 9:54AM $0.125 $23.240 risen by 18,492%
$2,946 Neuren receives Fast Track designation for Fragile X 18 Oct 2013 10:17AM $0.125 $23.240 risen by 18,492%
$2,946 Trading Halt 18 Oct 2013 10:15AM $0.125 $23.240 risen by 18,492%
$2,946 Response to ASX Price Query 9 Oct 2013 9:30AM $0.115 $23.240 risen by 20,108.70%
$2,946 Neuren opens new IND for NNZ-2566 in Fragile X Syndrome 9 Sep 2013 11:24AM $0.100 $23.240 risen by 23,140%
$2,946 Half Yearly Report and Accounts 29 Aug 2013 10:02AM $0.094 $23.240 risen by 24,623.40%
$2,946 Response to social media commentary re Rett trial 5 Aug 2013 2:06PM $0.100 $23.240 risen by 23,140%
$2,946 Trading Halt 5 Aug 2013 10:11AM $0.100 $23.240 risen by 23,140%
$2,946 Appendix 4C - quarterly 31 Jul 2013 9:54AM $0.096 $23.240 risen by 24,108.33%

651 - 675 of 835 results

Page 27 of 34

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.